Meeting
2020 ASCO Virtual Scientific Program
Employing RNA sequencing to enhance treatment options for cancer patients.
Authors
Gargi D. Basu
Ashion Analytics, Phoenix, AZ
Gargi D. Basu , Janine LoBello , Audrey Ozols
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3628)
DOI
10.1200/JCO.2020.38.15_suppl.3628
Abstract #
3628
Poster Bd #
358
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A cell-free RNA-based next-generation sequencing (NGS) assay for the detection of actionable gene fusions in patients with non–small cell lung cancer (NSCLC).
First Author: Yukti Choudhury
Poster
2022 ASCO Genitourinary Cancers Symposium
Expanding the use of targeted therapy for urothelial bladder cancer (UBC): Non-FGFR3 receptor tyrosine kinase (RTK) gene rearrangements (ReAr) and fusions (fus).
First Author: Andrea Necchi
Poster
2020 ASCO Virtual Scientific Program
Pan-tumor analyses of kinase fusions detected in circulating tumor DNA (ctDNA) and concordance with paired tissue.
First Author: Jessica Kim Lee
Poster
2019 ASCO Annual Meeting
Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).
First Author: Milind M. Javle